Jeffrey Graham1, J Connor Wells1, Frede Donskov2, Jae Lyun Lee3, Anna Fraccon4, Felice Pasini5, Camillo Porta6, I Alex Bowman7, Georg A Bjarnason8, D Scott Ernst9, Sun Young Rha10, Benoit Beuselinck11, Aaron Hansen12, Scott A North13, Christian K Kollmannsberger14, Lori A Wood15, Ulka N Vaishampayan16, Sumanta K Pal17, Toni K Choueiri18, Daniel Y C Heng19. 1. Tom Baker Cancer Centre, University of Calgary, Calgary, Canada. 2. Aarhus University Hospital, Aarhus, Denmark. 3. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. 4. CDC Pererzoli, Peschiera del Garda, Italy. 5. Oncologia Medica Ospedale Santa Maria della Misericordia, Rovigo, Italy. 6. University of Pavia, Pavia, Italy. 7. UT Southwestern Medical Center, Dallas, TX, USA. 8. Sunnybrook Research Institute, Toronto, Canada. 9. London Health Sciences Centre, London, Canada. 10. Yonsei University College of Medicine, Seoul, Republic of Korea. 11. University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. 12. Princess Margaret Cancer Centre, Toronto, Canada. 13. University of Alberta, Cross Cancer Institute, Edmonton, Canada. 14. British Columbia Cancer Agency, Vancouver, Canada. 15. QEII Health Sciences Centre, Halifax, Canada. 16. Karmanos Cancer Center, Detroit, MI, USA. 17. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 18. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 19. Tom Baker Cancer Centre, University of Calgary, Calgary, Canada. Electronic address: daniel.heng@ahs.ca.
Abstract
BACKGROUND: There is evidence that cytoreductive nephrectomy (CN) may be beneficial in metastatic renal cell carcinoma (mRCC). This has been studied predominantly in clear-cell RCC, with more limited data on the role of CN in patients with papillary histology. OBJECTIVE: To determine the benefit of CN in synchronous metastatic papillary RCC. DESIGN, SETTING, AND PARTICIPANTS: Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) database, a retrospective analysis was performed for patients with papillary mRCC treated with or without CN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Median overall survival (OS) and progression-free survival (PFS) were determined for both patient groups. Cox regression analysis was performed to control for imbalances in individual IMDC risk factors. RESULTS AND LIMITATIONS: In total, 647 patients with papillary mRCC were identified, of whom 353 had synchronous metastatic disease. Of these, 109 patients were treated with CN and 244 were not. The median follow-up was 57.1mo (95% confidence interval [CI] 32.9-77.8) and the OS from the start of first-line targeted therapy for the entire cohort was 13.2mo (95% CI 12.0-16.1). Median OS for patients with CN was 16.3mo, compared to 8.6mo (p<0.0001) in the no-CN group. When adjusted for individual IMDC risk factors, the hazard ratio (HR) of death for CN was 0.62 (95% CI 0.45-0.85; p=0.0031). Limitations include the retrospective nature of the analysis. CONCLUSIONS: The use of CN in patients with mRCC and papillary histology appears to be associated with better survival compared to no CN after adjustment for risk criteria. Selection of appropriate candidates for CN is crucial. A clinical trial in this rare population may not be possible. PATIENT SUMMARY: In a population of patients with advanced papillary kidney cancer, we found that surgical removal of the primary kidney tumor was associated with better overall survival.
BACKGROUND: There is evidence that cytoreductive nephrectomy (CN) may be beneficial in metastatic renal cell carcinoma (mRCC). This has been studied predominantly in clear-cell RCC, with more limited data on the role of CN in patients with papillary histology. OBJECTIVE: To determine the benefit of CN in synchronous metastatic papillary RCC. DESIGN, SETTING, AND PARTICIPANTS: Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) database, a retrospective analysis was performed for patients with papillary mRCC treated with or without CN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Median overall survival (OS) and progression-free survival (PFS) were determined for both patient groups. Cox regression analysis was performed to control for imbalances in individual IMDC risk factors. RESULTS AND LIMITATIONS: In total, 647 patients with papillary mRCC were identified, of whom 353 had synchronous metastatic disease. Of these, 109 patients were treated with CN and 244 were not. The median follow-up was 57.1mo (95% confidence interval [CI] 32.9-77.8) and the OS from the start of first-line targeted therapy for the entire cohort was 13.2mo (95% CI 12.0-16.1). Median OS for patients with CN was 16.3mo, compared to 8.6mo (p<0.0001) in the no-CN group. When adjusted for individual IMDC risk factors, the hazard ratio (HR) of death for CN was 0.62 (95% CI 0.45-0.85; p=0.0031). Limitations include the retrospective nature of the analysis. CONCLUSIONS: The use of CN in patients with mRCC and papillary histology appears to be associated with better survival compared to no CN after adjustment for risk criteria. Selection of appropriate candidates for CN is crucial. A clinical trial in this rare population may not be possible. PATIENT SUMMARY: In a population of patients with advanced papillary kidney cancer, we found that surgical removal of the primary kidney tumor was associated with better overall survival.
Authors: Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri Journal: Eur Urol Date: 2014-06-13 Impact factor: 20.096
Authors: Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: W Marston Linehan; Paul T Spellman; Christopher J Ricketts; Chad J Creighton; Suzanne S Fei; Caleb Davis; David A Wheeler; Bradley A Murray; Laura Schmidt; Cathy D Vocke; Myron Peto; Abu Amar M Al Mamun; Eve Shinbrot; Anurag Sethi; Samira Brooks; W Kimryn Rathmell; Angela N Brooks; Katherine A Hoadley; A Gordon Robertson; Denise Brooks; Reanne Bowlby; Sara Sadeghi; Hui Shen; Daniel J Weisenberger; Moiz Bootwalla; Stephen B Baylin; Peter W Laird; Andrew D Cherniack; Gordon Saksena; Scott Haake; Jun Li; Han Liang; Yiling Lu; Gordon B Mills; Rehan Akbani; Mark D M Leiserson; Benjamin J Raphael; Pavana Anur; Donald Bottaro; Laurence Albiges; Nandita Barnabas; Toni K Choueiri; Bogdan Czerniak; Andrew K Godwin; A Ari Hakimi; Thai H Ho; James Hsieh; Michael Ittmann; William Y Kim; Bhavani Krishnan; Maria J Merino; Kenna R Mills Shaw; Victor E Reuter; Ed Reznik; Carl S Shelley; Brian Shuch; Sabina Signoretti; Ramaprasad Srinivasan; Pheroze Tamboli; George Thomas; Satish Tickoo; Kenneth Burnett; Daniel Crain; Johanna Gardner; Kevin Lau; David Mallery; Scott Morris; Joseph D Paulauskis; Robert J Penny; Candace Shelton; W Troy Shelton; Mark Sherman; Eric Thompson; Peggy Yena; Melissa T Avedon; Jay Bowen; Julie M Gastier-Foster; Mark Gerken; Kristen M Leraas; Tara M Lichtenberg; Nilsa C Ramirez; Tracie Santos; Lisa Wise; Erik Zmuda; John A Demchok; Ina Felau; Carolyn M Hutter; Margi Sheth; Heidi J Sofia; Roy Tarnuzzer; Zhining Wang; Liming Yang; Jean C Zenklusen; Jiashan Zhang; Brenda Ayala; Julien Baboud; Sudha Chudamani; Jia Liu; Laxmi Lolla; Rashi Naresh; Todd Pihl; Qiang Sun; Yunhu Wan; Ye Wu; Adrian Ally; Miruna Balasundaram; Saianand Balu; Rameen Beroukhim; Tom Bodenheimer; Christian Buhay; Yaron S N Butterfield; Rebecca Carlsen; Scott L Carter; Hsu Chao; Eric Chuah; Amanda Clarke; Kyle R Covington; Mahmoud Dahdouli; Ninad Dewal; Noreen Dhalla; Harsha V Doddapaneni; Jennifer A Drummond; Stacey B Gabriel; Richard A Gibbs; Ranabir Guin; Walker Hale; Alicia Hawes; D Neil Hayes; Robert A Holt; Alan P Hoyle; Stuart R Jefferys; Steven J M Jones; Corbin D Jones; Divya Kalra; Christie Kovar; Lora Lewis; Jie Li; Yussanne Ma; Marco A Marra; Michael Mayo; Shaowu Meng; Matthew Meyerson; Piotr A Mieczkowski; Richard A Moore; Donna Morton; Lisle E Mose; Andrew J Mungall; Donna Muzny; Joel S Parker; Charles M Perou; Jeffrey Roach; Jacqueline E Schein; Steven E Schumacher; Yan Shi; Janae V Simons; Payal Sipahimalani; Tara Skelly; Matthew G Soloway; Carrie Sougnez; Angela Tam; Donghui Tan; Nina Thiessen; Umadevi Veluvolu; Min Wang; Matthew D Wilkerson; Tina Wong; Junyuan Wu; Liu Xi; Jane Zhou; Jason Bedford; Fengju Chen; Yao Fu; Mark Gerstein; David Haussler; Katayoon Kasaian; Phillip Lai; Shiyun Ling; Amie Radenbaugh; David Van Den Berg; John N Weinstein; Jingchun Zhu; Monique Albert; Iakovina Alexopoulou; Jeremiah J Andersen; J Todd Auman; John Bartlett; Sheldon Bastacky; Julie Bergsten; Michael L Blute; Lori Boice; Roni J Bollag; Jeff Boyd; Erik Castle; Ying-Bei Chen; John C Cheville; Erin Curley; Benjamin Davies; April DeVolk; Rajiv Dhir; Laura Dike; John Eckman; Jay Engel; Jodi Harr; Ronald Hrebinko; Mei Huang; Lori Huelsenbeck-Dill; Mary Iacocca; Bruce Jacobs; Michael Lobis; Jodi K Maranchie; Scott McMeekin; Jerome Myers; Joel Nelson; Jeremy Parfitt; Anil Parwani; Nicholas Petrelli; Brenda Rabeno; Somak Roy; Andrew L Salner; Joel Slaton; Melissa Stanton; R Houston Thompson; Leigh Thorne; Kelinda Tucker; Paul M Weinberger; Cynthia Winemiller; Leigh Anne Zach; Rosemary Zuna Journal: N Engl J Med Date: 2015-11-04 Impact factor: 91.245
Authors: Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: John Connor Wells; Frede Donskov; Anna P Fraccon; Felice Pasini; Georg A Bjarnason; Benoit Beuselinck; Jennifer J Knox; Sun Young Rha; Neeraj Agarwal; Isaac Alex Bowman; Jae-Lyun Lee; Sumanta K Pal; Sandy Srinivas; Douglas Scott Ernst; Ulka N Vaishampayan; Lori A Wood; Robin Simpson; Guillermo De Velasco; Toni K Choueiri; Daniel Y C Heng Journal: Cancer Med Date: 2017-04-16 Impact factor: 4.452
Authors: Toni K Choueiri; Daniel Y C Heng; Jae Lyun Lee; Mathilde Cancel; Remy B Verheijen; Anders Mellemgaard; Lone H Ottesen; Melanie M Frigault; Anne L'Hernault; Zsolt Szijgyarto; Sabina Signoretti; Laurence Albiges Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777